zyprexa

Citigroups' Jonathan Eckard, Ph.D. continues to believe that Alkermes Plc (NASDAQ: ALKS) is a top name among biotech stocks and remains on the Citi U.S. Focus List. On Wednesday, Eckard increased his price target on Buy-rated Alkermes to $85 from a previous $72, reflecting the belief that...

Citigroup has published a research report for Eli Lilly (NYSE: LLY) reporting on core product trends for the week ending on 9/24. In the report, Citigroup writes " Effient: 2.7% NRx's of Plavix Market; We Assume 2010 US Sales of $100M. Effient weekly NRx/TRx of 5,691 (+3% seq.)/13,578(+2%) vs....